FQ2 beats across the board despite a 3% decline in sales.
Adjusted claims from continuing operations fell 7% from Q212, reflecting the expected roll-off of claims from United Healthcare Group.
For Q3, the company anticipates its EPS to come in between $1.05 - $1.09, versus the Street estimates of $1.08.
FY13 EPS is expected to be around $4.26 to $4.34, up from prior guidance of $4.23 - $4.33. Analysts are looking for $4.29.
Subscribe for full text news in your inbox